A Comparative Review of Autologous Conditioned Serum and Autologous Protein Solution for Treatment of Osteoarthritis in Horses

Garbin, Livia Camargo; Morris, Michael

doi:10.3389/fvets.2021.602978

Cited by 20 publications

(22 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OA has a considerable economic impact on the equine industry, with the annual direct and indirect costs amounting to over $1 billion per year in the United States ( 7 , 8 ). There is no cure for OA and treatment primarily revolves around managing symptoms by systemic and local pharmacological therapies including analgesics and non-steroidal anti-inflammatory agents (NSAIDs) ( 9 ), surgical approaches such as microfracture and chondroplasty ( 10 – 13 ), and regenerative medicine strategies using blood derived (ACS, APS, and PRP) ( 14 – 17 ) or cell-based approaches (ACI/MACI) ( 18 – 22 ). However, these are only effective at providing short-term relief and do not alter disease progression nor do they completely restore cartilage structure and function ( 4 , 23 ).…”

Section: Introductionmentioning

confidence: 99%

Gene therapy approaches for equine osteoarthritis

Thampi

Samulski²,

Grieger³

et al. 2022

Front. Vet. Sci.

View full text Add to dashboard Cite

With an intrinsically low ability for self-repair, articular cartilage injuries often progress to cartilage loss and joint degeneration resulting in osteoarthritis (OA). Osteoarthritis and the associated articular cartilage changes can be debilitating, resulting in lameness and functional disability both in human and equine patients. While articular cartilage damage plays a central role in the pathogenesis of OA, the contribution of other joint tissues to the pathogenesis of OA has increasingly been recognized thus prompting a whole organ approach for therapeutic strategies. Gene therapy methods have generated significant interest in OA therapy in recent years. These utilize viral or non-viral vectors to deliver therapeutic molecules directly into the joint space with the goal of reprogramming the cells' machinery to secrete high levels of the target protein at the site of injection. Several viral vector-based approaches have demonstrated successful gene transfer with persistent therapeutic levels of transgene expression in the equine joint. As an experimental model, horses represent the pathology of human OA more accurately compared to other animal models. The anatomical and biomechanical similarities between equine and human joints also allow for the use of similar imaging and diagnostic methods as used in humans. In addition, horses experience naturally occurring OA and undergo similar therapies as human patients and, therefore, are a clinically relevant patient population. Thus, further studies utilizing this equine model would not only help advance the field of human OA therapy but also benefit the clinical equine patients with naturally occurring joint disease. In this review, we discuss the advancements in gene therapeutic approaches for the treatment of OA with the horse as a relevant patient population as well as an effective and commonly utilized species as a translational model.

show abstract

Section: Introductionmentioning

confidence: 99%

Gene therapy approaches for equine osteoarthritis

Thampi

Samulski²,

Grieger³

et al. 2022

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…51,53 Both ACS and APS have similar symptom-modifying effects in joints, and both have not been shown to have disease-modifying effects. 64 APS is often used because of the pointof-care same-day processing and the need for only 1 injection of APS for effective treatment. 51,53,64 However, in a survey of board-certified equine specialists, ACS was used more commonly than APS for treatment of joint inflammation.…”

Section: Acs Processing and Protocolmentioning

confidence: 99%

A one-health perspective: use of hemoderivative regenerative therapies in canine and equine patients

Kaneps¹

2023

javma

View full text Add to dashboard Cite

Regenerative medicine therapies have become significant tools for treatment of joint, soft tissue, and a variety of other conditions in animals and humans. Regenerative medicine aims to restore form and function of injured tissues using the body’s own resources such as cells, fluids (ie, plasma and serum), and their resulting anti-inflammatory and prohealing cytokines. Platelet-rich plasma and other hemoderivatives have application for joint disorders such as osteoarthritis, cartilage injury, synovitis, and soft tissue injuries. These therapies achieve anti-inflammatory and healing effects without the use of corticosteroid therapy. This response is an advantage when treating young animals or human patients, and in animals with metabolic or hormonal issues such as equine pituitary pars intermedia dysfunction. Also, these therapies may have beneficial effects when traditional IA treatments such as corticosteroids and/or hyaluronan are no longer effective at reducing joint inflammation and pain. Examples of hemoderivative regenerative therapies to be discussed include platelet-rich plasma, autologous conditioned serum, autologous protein solution, and α-2 macroglobulin.

show abstract

“…The disease is primarily an irreversible, incurable, non-regenerative condition with long-term complications despite receiving standard therapy typically including a combination of pain control medication, joint supplement, and physiotherapy [ 2 , 5 , 6 ]. An alternative intervention to alleviate joint inflammation is using cytokine inhibitors specifically the Interleukin-1 Receptor Antagonist (IL-1RA) [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…Competitive binding at the IL-1 receptor by IL-1RA is considered the primary action inhibiting the joint’s inflammatory process [ 7 , 9 ]. Studies have shown that IL-1RA prevents IL-1 ligand activation resulting in reduced synthesis of mediators such as metalloproteinases (MMPs), cyclooxygenase-2 (COX2), prostaglandins, and nitrous oxide that propagate OA [ 1 , 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…Thus, ACS is considered a safe and practical biological product, with the promising therapeutic effect on OA. The articular injection with ACS has become widely used in clinic with favorable treatment outcome in humans [ 8 , 18 , 19 ] and companion animals [ 7 , 20 , 21 ]. Noteworthy, the secretory mediators vary among the species and individuals [ 8 , 15 , 22 ], which is a common issue observed in hemoderivative products.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Anti-Inflammatory and Regenerative Effects of Autologous Conditioned Serum from Dogs with Osteoarthritis

Soontararak

Ardaum

Senarat

et al. 2022

Animals

View full text Add to dashboard Cite

Osteoarthritis (OA) is mostly incurable and non-regenerative with long-term complications. Autologous conditioned serum (ACS), which is enriched in Interleukin 1 receptor antagonists (IL-1RA) and growth factors, could be an alternative treatment to accelerate the positive therapeutic effects. ACS is proposed to alleviate inflammation by blocking IL-1 receptors. However, to date, there is no report focusing on the cell-mediated anti-inflammation and regenerative effect caused by ACS, especially the ACS from patients. Therefore, this study aims to investigate the therapeutic potential of ACS generated from dogs with spontaneous OA, focusing on its promising anti-inflammatory and regenerative properties in vitro compared to the matched plasma. We found that ACS prepared from ten OA dogs contained significant concentrations of IL-1RA, vascular endothelial growth factor, and transforming growth factor beta, which are key cytokines in anti-inflammation and angiogenesis. Furthermore, we found that ACS suppressed T cell activity by reducing proliferation of effector T cells and simultaneously expanding numbers of immune suppressive FOXP3+ T cells. Lastly, we showed that ACS enhanced the proliferation of osteocytes and fibroblasts and promoted extracellular matrix gene expression in primary chondrocyte culture. Therefore, these studies indicate that ACS prepared from dogs with OA is active as an immunomodulatory and regenerative strategy for use in OA management.

show abstract

A Comparative Review of Autologous Conditioned Serum and Autologous Protein Solution for Treatment of Osteoarthritis in Horses

Cited by 20 publications

References 54 publications

Gene therapy approaches for equine osteoarthritis

Gene therapy approaches for equine osteoarthritis

A one-health perspective: use of hemoderivative regenerative therapies in canine and equine patients

In Vitro Anti-Inflammatory and Regenerative Effects of Autologous Conditioned Serum from Dogs with Osteoarthritis

Contact Info

Product

Resources

About